Skip to content

Startup & venture capital news

Emvena receives undisclosed seed investment

Penn BioNTech fund backs maternal health mRNA research

By /

LinkedInX
Emvena Therapeutics: Emvena receives undisclosed seed investment

Philadelphia based Emvena Therapeutics announced an investment from the Penn BioNTech Innovative Therapeutics Seed Fund on 4 November 2026. The amount was explicitly not disclosed. Emvena is developing mRNA medicines for serious maternal and fetal health conditions, beginning with preeclampsia. The investment is the first made by the fund, which was established by the University of Pennsylvania and BioNTech to support therapeutic research originating from Penn. Emvena plans to advance its lead programme and generate the preclinical evidence required for further development. The financing combines academic science with specialist capital for a condition with limited treatment options.

Keep reading

More Funding

All stories